The potent PARP inhibitor, talazoparib (BMN 673), inhibited CD40L-stimulated proliferation of CLL cells at nM concentrations, independently of Binet stage or p53/ATM function. The gene discussed is CD40LG; the disease is B-cell chronic lymphocytic leukemia.